MDXG (MiMedx Group) Moat Score: 5/10 (As of Jun. 29, 2026)


MDXG MiMedx Group Inc MDXG
57 GF Score
Price $3.91
GF Value $6.96
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Moat Score?

MiMedx Group MDXG -0.51% 57 Moat Score is 5 as of Jun. 29, 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, MiMedx Group ranks better than 96.72% on this metric.

MiMedx Group has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

MiMedx Group has Narrow Moat: MiMedx has a solid narrow moat due to its proprietary regenerative biomaterials and patents. It benefits from some customer loyalty and regulatory barriers, but faces competition that limits its market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MiMedx Group might have Narrow Moat - Solid narrow moat.

MiMedx Group  (NAS:MDXG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MiMedx Group Moat Score Related Terms

MDXG vs MNPR, FTH, BBOT: Moat Score Comparison

For the Biotechnology subindustry, MiMedx Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiMedx Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Moat Score distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Moat Score falls into.


MDXG
57GF Score
MiMedx Group Inc MDXG
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
MiMedx Group (MDXG) has a Moat Score of 5 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, MiMedx Group ranks #46 out of 1401 companies in the Biotechnology industry, placing it in the top 3.3%.
Is MiMedx Group's Moat Score too high?
MiMedx Group's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. MiMedx Group's value of 5 is 150% above this industry median. Based on the distribution chart, MiMedx Group ranks #46 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Moat Score compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #46 out of 1401 companies for Moat Score. This places MiMedx Group in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. MiMedx Group's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.91 — trading 43.8% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Moat Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $3.91 is trading 43.8% below its estimated GF Value™ of $6.96. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Moat Score: 5
  • GF Value™: $6.96 vs. price of $3.91 (43.8% below fair value)
  • GF Score™: 57/100 with 2 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1401)

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.91
Price
$6.96
GF Value